A 62-year-old woman with metastatic adenocarcinoma of the lung (stage IV) undergoes molecular testing. The tumor is found to be EGFR-mutant (exon 19 deletion) and PD-L1 negative. She has no prior chemotherapy. Which of the following is the drug of choice for first-line treatment?

Explanation

## First-Line Treatment of EGFR-Mutant Metastatic NSCLC **Key Point:** Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is the preferred first-line treatment for EGFR-mutant metastatic NSCLC, regardless of PD-L1 status. ### EGFR-Mutant NSCLC: Treatment Paradigm Shift 1. **Osimertinib superiority**: The FLAURA trial (2017) demonstrated that osimertinib as first-line monotherapy provides superior progression-free survival (PFS) and overall survival (OS) compared to first-generation EGFR TKIs (gefitinib, erlotinib) in treatment-naïve EGFR-mutant patients. 2. **Mechanism**: Osimertinib irreversibly inhibits EGFR tyrosine kinase and is active against common EGFR mutations (exon 19 deletions and L858R point mutations) and resistant T790M mutations. 3. **Oral bioavailability**: As a small-molecule TKI, osimertinib offers convenient oral dosing with excellent CNS penetration, making it ideal for patients with brain metastases. 4. **PD-L1 status irrelevant**: Unlike immunotherapy, EGFR TKI efficacy is independent of PD-L1 expression; molecular mutation status, not immune status, drives treatment selection. ### Treatment Algorithm for Metastatic NSCLC by Molecular Profile ```mermaid flowchart TD A[Metastatic NSCLC]:::outcome --> B{Molecular testing}:::decision B -->|EGFR-mutant| C[Osimertinib monotherapy]:::action B -->|ALK-rearranged| D[Alectinib or crizotinib]:::action B -->|ROS1-rearranged| E[Crizotinib]:::action B -->|PD-L1 ≥50%| F[Pembrolizumab monotherapy]:::action B -->|PD-L1 <50% or negative| G[Chemotherapy ± bevacizumab/immunotherapy]:::action C --> H[Osimertinib 80 mg daily]:::action H --> I[Reassess at 8-12 weeks]:::action ``` ### Comparison of First-Line Options in EGFR-Mutant Disease | Regimen | Indication | Mechanism | PFS (months) | Notes | |---------|-----------|-----------|--------------|-------| | Osimertinib | EGFR-mutant, treatment-naïve | 3rd-gen EGFR TKI | ~18–19 | Gold standard; FLAURA trial | | Gefitinib/Erlotinib | EGFR-mutant, treatment-naïve | 1st-gen EGFR TKI | ~10–13 | Inferior to osimertinib; rarely used now | | Cisplatin + pemetrexed ± bevacizumab | EGFR wild-type or unknown | Chemotherapy | ~8–10 | Not first-line for known EGFR-mutant | | Pembrolizumab monotherapy | PD-L1 ≥50%, EGFR/ALK wild-type | Anti-PD-1 | ~7–10 | Not effective in EGFR-mutant disease | **High-Yield:** **EGFR-mutant = osimertinib first-line.** This is a high-yield, frequently tested concept. Molecular testing is mandatory before treatment selection in metastatic NSCLC. **Mnemonic:** **EGFR TKI Generations** — **1st Gen (Gefitinib, Erlotinib) → 2nd Gen (Afatinib) → 3rd Gen (Osimertinib, Rociletinib)**. Osimertinib is the current standard because it covers both sensitizing mutations and T790M resistance mutations. **Clinical Pearl:** Osimertinib is also the treatment of choice for EGFR-mutant NSCLC with CNS metastases due to excellent blood–brain barrier penetration, unlike earlier-generation TKIs. **Warning:** Do not use pembrolizumab monotherapy in EGFR-mutant disease — EGFR-mutant tumors are typically PD-L1 negative and immunotherapy-resistant. Immunotherapy is reserved for EGFR wild-type, ALK wild-type ("triple-negative") tumors with high PD-L1 expression. [cite:Harrison 21e Ch 107; NCCN Guidelines for Non-Small Cell Lung Cancer 2023]